A randomized controlled trial of azithromycin and sulphadoxine-pyrimethamine as prophylaxis against malaria in pregnancy among human immunodeficiency virus-positive women
© The Author(s) 2019. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Malaria and human immunodeficiency virus (HIV) infections in pregnancy are important and major contributing factors to maternal morbidity and mortality in sub-Saharan Africa. Prevention of malaria in HIV-positive pregnant woman will reduce the burden of malaria-HIV comorbidity. The objective of this study was to compare effects and safety of azithromycin (AZ) with sulphadoxine-pyrimethamine (SP) for intermittent preventive therapy for malaria in HIV-positive pregnant women.
METHODS: We performed a randomized, controlled, open-label pregnancy trial of 140 HIV-positive pregnant patients attending antenatal clinics at the University College Hospital and Adeoyo Maternity Teaching Hospital, Ibadan, Nigeria. Participants were enrolled from a gestational age of 16 weeks and randomized to receive AZ or SP. The primary outcome was peripheral parasitaemia at delivery. Secondary outcomes were drug tolerability, foetal outcome and birthweight. The χ2 test (or Fisher's exact test, as appropriate) and Student's t test were used in the per-protocol analysis. The level of statistical significance was p<0.05.
RESULTS: A total of 123 participants (87.9%) completed the study: 60 participants received AZ and 63 received SP. The incidence of malaria parasitaemia at delivery in the AZ group was 6 (10.0%), compared with 7 (11.1%) in the SP group (relative risk 0.89 [95% confidence interval 0.28 to 2.82], p=0.84). Placental parasitization was demonstrated in 1 (1.6%) participant in the SP group compared with 3 (5.0%) in the AZ group (p=0.36).
CONCLUSIONS: The findings suggest that AZ is comparable to SP in malaria prevention and safety in HIV-positive pregnant women.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
Transactions of the Royal Society of Tropical Medicine and Hygiene - 113(2019), 8 vom: 01. Aug., Seite 463-470 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Akinyotu, Oriyomi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.08.2020 Date Revised 20.08.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/trstmh/trz028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29758460X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29758460X | ||
| 003 | DE-627 | ||
| 005 | 20231225092314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/trstmh/trz028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0991.xml |
| 035 | |a (DE-627)NLM29758460X | ||
| 035 | |a (NLM)31140565 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Akinyotu, Oriyomi |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A randomized controlled trial of azithromycin and sulphadoxine-pyrimethamine as prophylaxis against malaria in pregnancy among human immunodeficiency virus-positive women |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.08.2020 | ||
| 500 | |a Date Revised 20.08.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2019. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Malaria and human immunodeficiency virus (HIV) infections in pregnancy are important and major contributing factors to maternal morbidity and mortality in sub-Saharan Africa. Prevention of malaria in HIV-positive pregnant woman will reduce the burden of malaria-HIV comorbidity. The objective of this study was to compare effects and safety of azithromycin (AZ) with sulphadoxine-pyrimethamine (SP) for intermittent preventive therapy for malaria in HIV-positive pregnant women | ||
| 520 | |a METHODS: We performed a randomized, controlled, open-label pregnancy trial of 140 HIV-positive pregnant patients attending antenatal clinics at the University College Hospital and Adeoyo Maternity Teaching Hospital, Ibadan, Nigeria. Participants were enrolled from a gestational age of 16 weeks and randomized to receive AZ or SP. The primary outcome was peripheral parasitaemia at delivery. Secondary outcomes were drug tolerability, foetal outcome and birthweight. The χ2 test (or Fisher's exact test, as appropriate) and Student's t test were used in the per-protocol analysis. The level of statistical significance was p<0.05 | ||
| 520 | |a RESULTS: A total of 123 participants (87.9%) completed the study: 60 participants received AZ and 63 received SP. The incidence of malaria parasitaemia at delivery in the AZ group was 6 (10.0%), compared with 7 (11.1%) in the SP group (relative risk 0.89 [95% confidence interval 0.28 to 2.82], p=0.84). Placental parasitization was demonstrated in 1 (1.6%) participant in the SP group compared with 3 (5.0%) in the AZ group (p=0.36) | ||
| 520 | |a CONCLUSIONS: The findings suggest that AZ is comparable to SP in malaria prevention and safety in HIV-positive pregnant women | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a HIV pregnancy | |
| 650 | 4 | |a azithromycin | |
| 650 | 4 | |a intermittent preventive therapy | |
| 650 | 4 | |a malaria in pregnancy | |
| 650 | 4 | |a malaria prophylaxis | |
| 650 | 4 | |a sulphadoxine–pyrimethamine | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a fanasil, pyrimethamine drug combination |2 NLM | |
| 650 | 7 | |a 37338-39-9 |2 NLM | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 650 | 7 | |a Sulfadoxine |2 NLM | |
| 650 | 7 | |a 88463U4SM5 |2 NLM | |
| 650 | 7 | |a Pyrimethamine |2 NLM | |
| 650 | 7 | |a Z3614QOX8W |2 NLM | |
| 700 | 1 | |a Bello, Folasade |e verfasserin |4 aut | |
| 700 | 1 | |a Abdus-Salam, Rukiyat |e verfasserin |4 aut | |
| 700 | 1 | |a Arowojolu, Ayodele |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transactions of the Royal Society of Tropical Medicine and Hygiene |d 1945 |g 113(2019), 8 vom: 01. Aug., Seite 463-470 |w (DE-627)NLM000035653 |x 1878-3503 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:2019 |g number:8 |g day:01 |g month:08 |g pages:463-470 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/trstmh/trz028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 113 |j 2019 |e 8 |b 01 |c 08 |h 463-470 | ||